Compare Amgen, Inc. (AMGN) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Gap Inc — how do they compare? Amgen, Inc. trades at $356.71 (market cap $196.12B), while Gap Inc trades at $19.62 (market cap $7.01B). The key difference: Amgen, Inc. is far larger — about 28× Gap Inc's market cap, and Gap Inc pays the higher dividend (3.6%). Which is the better fit depends on your goals.
| AMGN | GAP | |
|---|---|---|
Market Cap | $196.12B | $7.01B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $29.13 |
52-Week Low | $271.18 | $18.35 |
Enterprise Value | $241.41B | $10.09B |
Dividend Yield | 2.77% | 3.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Gap Inc. (GAP) trades at $19.46, up 3.24% today, with a bearish technical outlook but attractive valuation metrics including a P/E of 7.72 and P/S of 0.48. Recent earnings show mixed results with a Q1 2026 beat but a Q4 2025 miss. The company demonstrates strong profitability with a net income margin of 6.25% and ROE of 27.58%, supported by positive operating cash flow of $1.49 billion in 2025. News highlights include ongoing investigations by law firms and digital transformation efforts.
The stock presents a value opportunity with a consensus price target of $27.00, implying significant upside, but faces risks from legal scrutiny and competitive pressures. Analyst sentiment is mixed with 39.58% buy ratings, while technical indicators suggest near-term weakness. Revenue growth remains modest, projected at $15.4 billion for 2026, with earnings stability key to unlocking value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
